Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion (Soban News)

This is Gilead’s biggest deal since its $21 billion buyout of Immunomedics, giving it access to Trodelvy, an antibody-drug conjugate used to treat a type of advanced breast cancer​This is Gilead’s biggest deal since its $21 billion buyout of Immunomedics, giving it access to Trodelvy, an antibody-drug conjugate used to treat a type of advanced breast cancer ​Latest News [ SOBAN NEWS: International and National ]